Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 11 clients • 12 examiners • 8 art units • 0 of 14 (0%) have an AI response strategy ready
Nevrivy Patent Law Group P.L.L.C. operates in the Biotechnology & Pharmaceuticals technology area. The firm has managed 460 career applications and currently oversees 12 pending office actions. These figures indicate the firm's historical experience and its current level of engagement with the USPTO. This data provides a baseline for understanding the firm's presence in this sector.
The firm's resolved allowance rate is 84.42. On average, the firm receives 4.56 office actions per allowance. Practitioners can use this average to estimate the frequency of examiner interactions required to reach a grant for applications in this portfolio. These metrics offer an overview of the firm's prosecution results.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (7%) |
| §102 only | 2 (14%) |
| §112 only | 3 (21%) |
| Double-patenting + other | 1 (7%) |
| Multi-statute (no §101) | 7 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREEN, KIMBERLY CATHERINE | 2 | 23.8% | +56.9% |
| MINCHELLA, KAITLYN L | 2 | 26.7% | +21.8% |
| FERNANDEZ, SUSAN EMILY | 1 | 52.5% | +60.8% |
| RAGHU, GANAPATHIRAM | 1 | 73.6% | +26.4% |
| KIM, JAY C | 1 | 49.3% | +21.6% |
| MORELLO, JEAN F | 1 | 68.6% | +9.0% |
| CHATTIN, AMY MARIE | 1 | 73.6% | +44.0% |
| DEVI, SARVAMANGALA | 1 | 65.3% | +55.3% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| HIBSHMAN, SARAH GRACE | 1 | 38.9% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17255570 | METHODS OF TREATING OR PREVENTING MUCORMYCOSIS | CHEONG, CHEOM-GIL | 25d overdue |
| 15028253 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | MINCHELLA, KAITLYN L | 14d |
| 15489658 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | MINCHELLA, KAITLYN L | 21d |
| 18988370 | FREEZE-DRIED PROBIOTIC FOODSTUFFS | FERNANDEZ, SUSAN EMILY | — |
| 18852356 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | RAGHU, GANAPATHIRAM | — |
| 18827601 | DETECTION OF CREATINE LEVELS USING ENZYME COMPOSITIONS | BREEN, KIMBERLY CATHERINE | — |
| 18691382 | INTERNAL DUCT INTEGRITY INSPECTION EQUIPMENT USING MAGNETIC METAL MEMORY | MORELLO, JEAN F | — |
| 17172860 | COMPOSITIONS COMPRISING PROBIOTICS AND METHODS OF USE THEREOF | BREEN, KIMBERLY CATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909423 | LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS PROTEIN ANTIGENS AND METHODS OF USE THEREOF | DEVI, SARVAMANGALA | 18d overdue |
| 15028253 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | MINCHELLA, KAITLYN L | 14d |
| 15489658 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | MINCHELLA, KAITLYN L | 21d |
| 17616584 | ADJUVANTS FOR IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | HIBSHMAN, SARAH GRACE | 34d |
| 18988370 | FREEZE-DRIED PROBIOTIC FOODSTUFFS | FERNANDEZ, SUSAN EMILY | — |
| 18852356 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | RAGHU, GANAPATHIRAM | — |
| 18827601 | DETECTION OF CREATINE LEVELS USING ENZYME COMPOSITIONS | BREEN, KIMBERLY CATHERINE | — |
| 18818538 | TUNED MATERIALS, TUNED PROPERTIES, AND TUNABLE DEVICES FROM ORDERED OXYGEN VACANCY COMPLEX OXIDES | KIM, JAY C | — |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1685 | 2 |
| 1651 | 1 |
| 2855 | 1 |
| 1643 | 1 |
| 1624 | 1 |
| 1693 | 1 |
| 1657 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18988370 | FREEZE-DRIED PROBIOTIC FOODSTUFFS | Imagilin Technology, LLC | FERNANDEZ, SUSAN EMILY | 1651 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18852356 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE | The United States Department of Veterans Affairs | RAGHU, GANAPATHIRAM | §102§103§112 | Non-Final OA | — | Pending | Sep 27, 2024 | |
| 18827601 | DETECTION OF CREATINE LEVELS USING ENZYME COMPOSITIONS | Ip2Ipo Innovations Limited | BREEN, KIMBERLY CATHERINE | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 | |
| 18818538 | TUNED MATERIALS, TUNED PROPERTIES, AND TUNABLE DEVICES FROM ORDERED OXYGEN VACANCY COMPLEX OXIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KIM, JAY C | §112 | Non-Final OA | — | Pending | Aug 28, 2024 | |
| 18691382 | INTERNAL DUCT INTEGRITY INSPECTION EQUIPMENT USING MAGNETIC METAL MEMORY | Pipeway Engenharia Ltda | MORELLO, JEAN F | 2855 | §102§103§112 | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18451671 | DETECTION OF ACUTE MYELOID LEUKAEMIA | Oxford University Innovation Limited | CHATTIN, AMY MARIE | 1643 | §102 | Final Rejection | — | Pending | Aug 17, 2023 |
| 17909423 | LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS PROTEIN ANTIGENS AND METHODS OF USE THEREOF | National Research Council Of Canada | DEVI, SARVAMANGALA | 1645 | §112 | Final Rejection | 18d overdue | Pending | Sep 05, 2022 |
| 17625059 | TREATMENT OF PULMONARY FIBROSIS USING INHIBITORS OF NEU1 SIALIDASE | The United States Department of Veterans Affairs | COLEMAN, BRENDA LIBBY | 1624 | §102 | Non-Final OA | — | Pending | Jan 05, 2022 |
| 17616584 | ADJUVANTS FOR IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | HIBSHMAN, SARAH GRACE | 1693 | §103 | Final Rejection | 34d | Pending | Dec 03, 2021 |
| 17172860 | COMPOSITIONS COMPRISING PROBIOTICS AND METHODS OF USE THEREOF | Imagilin Technology LLC | BREEN, KIMBERLY CATHERINE | 1657 | §103DP | Final Rejection | — | Pending | Feb 10, 2021 |
| 17255570 | METHODS OF TREATING OR PREVENTING MUCORMYCOSIS | Los Angeles Biomedical Research Institute AT Harbor AT Ucla Medical Center | CHEONG, CHEOM-GIL | 1645 | §103§112 | Final Rejection | 25d overdue | Pending | Dec 23, 2020 |
| 16331863 | THERMOSTABLE VARIANTS OF P. FALCIPARUM PFRH5 WHICH CAN BE PRODUCED IN BACTERIAL CELLS | Yeda Research And Development Co. Ltd. | ZEMAN, ROBERT A | 1645 | §112 | Final Rejection | — | Pending | Mar 08, 2019 |
| 15489658 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | UNIVERSITY OF MARYLAND, BALTIMORE | MINCHELLA, KAITLYN L | 1685 | §103§112 | Final Rejection | 21d | Pending | Apr 17, 2017 |
| 15028253 | METHODS FOR DISTINGUISHING INFLAMMATORY BOWEL DISEASES USING MICROBIAL COMMUNITY SIGNATURES | UNIVERSITY OF MARYLAND, BALTIMORE | MINCHELLA, KAITLYN L | 1685 | §102§112Other | Final Rejection | 14d | Pending | Apr 08, 2016 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial